SOLICITATION NOTICE
66 -- Acquisition of a Brand Name Mantis Liquid Dispenser
- Notice Date
- 7/17/2014
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 1050, Frederick, Maryland, 21702, United States
- ZIP Code
- 21702
- Solicitation Number
- N02RC42569-57
- Archive Date
- 8/15/2014
- Point of Contact
- Reyes Rodriguez, Phone: 240-276-5442, Terry L. Galloway, Phone: 240-276-5384
- E-Mail Address
-
reyes.rodriguez@nih.gov, gallowaytl@mail.nih.gov
(reyes.rodriguez@nih.gov, gallowaytl@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Developmental Therapeutics Branch (DTB), plans to procure on a sole source basis a Mantis Liquid Dispenser from Formulatrix, Inc., 1254 Main Street, Waltham, MA 02451, USA. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(1) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 334516 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. Delivery of the instrument shall occur 20 weeks After Receipt of Order (ARO) The NCI, CCR, Developmental Therapeutics Branch (DTB) focuses on the discovery and the molecular pharmacology of novel anticancer agents. Human tyrosyl phosphodiesterase 1 and 2 proteins (TDP1 and TDP2) are novel rational anticancer targets involved in the repair of DNA lesions created by the trapping of human DNA topoisomerase I and II (Top1 and Top2) following treatment by anticancer agents such as camptothecin and etoposide. Experimental observations suggest that the use of TDP1 with Top1 inhibitors or TDP2 with Top2 inhibitors in a combinational regimen are synergistic. DTB has developed a drug development effort for the discovery TDP1 and TDP2 specific inhibitors. The DTB has implemented several high throughput-screening (HTS) assays to discover TDP1 and TDP2 specific inhibitors. These plate-based assays are run in a 384-well format and require the handling of a large number of plates. The acquisition of a Mantis Liquid Dispenser is required for the DTB to continue its successful drug development effort for the discovery TDP1 and TDP2 specific inhibitors. The following salient characteristics apply to the Mantis Liquid Dispenser: • Capable of dispensing any volume of any ingredient into any plate well. • Capable of automatically dispensing up to 6 reagents in parallel without manual intervention. • Capable of dispensing with precision volumes as low as 100 nanoliters, without upper volume limit. • Capable of filling and dispensing as rapidly as 10 times per second. • Capable of a low dead volume of 6 microliters. • Capable of dispensing volumes from 5 microliters to 2000 microliters in an uninterrupted stream. • Capable of dispensing DMSO reagents via use of perfluoroelastomer chips. • Capable of dispensing DNase, RNase, and protease free solutions with molecular biology grade chips tested to be free of contamination. • Provides accurate and precise non-contact delivery of desired volumes of liquids into wells via patented micro-diaphragm pump technology. • Liquid can be dispensed in 96, 384 and 1536 well microplates, as well as deepwell blocks and vials. • Capable of high precision with CV's of < 3% for silicone based diaphragm chips and < 5% for PFE and Continuous Flow chips. • Provides software that is extremely user friendly and allows for simple drag and drop experimental design. Standard gradient and backfill buttons make designing an experiment even easier and faster. • Offers a very small footprint with dimensions of: 212 mm (8.35") x 175 mm (6.89") x 230 mm (9.06") only needing to be connected to a regular power source and computer. As a result, the instrument hardly takes space in the lab, and can easily be moved to other lab spaces in a matter of minutes if and when needed without any support that would need to be paid for. • Offers the following cost and time savings: - low volume dispensing saving precious reagents, - low dead volume saving precious reagents, - no clogging issues preventing failed experiments saving reagents - no learning curve for software operation and experimental - fast dispensing of higher volumes with Continuous Flow option, - no consumables as chips can be washed and reused. • Offers built-in dual wash stations to allow easy fluid pathway cleaning. • Must include at least a 12 months warranty on parts and labor. Currently, The Mantis Liquid Dispenser from Formulatrix is the only product in the world that utilizes patented microdiaphragm pump technology to provide accurate and precise non-contact delivery of desired volumes of liquids into wells of SBS based 96, 384 and 1536 well microplates, as well as deep well blocks and vials. Therefore, Formulatrix, Inc., is the only vendor available to provide the system due to the unique nature of the equipment. This notice is not a request for competitive quotation. However, if any interested party, especially small business believes it can meet the above requirement, it may submit a proposal or quote for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 11 AM EST, on July 31, 2014. All responses and questions must be in writing and faxed to 240-276-5399 or emailed to Reyes Rodriguez, Contracting Specialist via electronic mail at reyes.rodriguez@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through sam.gov. Reference: N02RC42569-57 on all correspondence. Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Bethesda, MD 20892, UNITED STATES
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF/N02RC42569-57/listing.html)
- Place of Performance
- Address: TBD, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03429100-W 20140719/140717235747-e8da80011f9080bb7392f072c890597b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |